Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system and is a highly expressed protein in multiple myeloma. Isatuximab has antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, which can directly induce apoptosis in the absence of crosslinking. Isatuximab has an inhibitory effect on CD38 extracellular enzyme activity, which is associated with many cellular functions.

Isatuximab与Pomalidomide（一种免疫调节药物）的联合使用相比于单独使用Isatuximab，能够更有效地增强效应细胞直接对CD38多发性骨髓瘤细胞的毒性和溶解作用[2]。